PD-1抑制剂联合化疗在Ⅲ/Ⅳ期结外鼻型自然杀伤/T细胞淋巴瘤一线治疗中的疗效与安全性
[Efficacy and safety of PD-1 inhibitor combined with chemotherapy in the primary treatment of phase Ⅲ/Ⅳ extranodal nasal-type natural killer/T cell lymphoma].
作者信息
Liu Y B, Yuan X L, Ma R J, Jiang L, Wang L F, Zhu Z M
机构信息
Department of Hematology, People's Hospital of Zhengzhou University, Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou 450003, China.
Department of Pathology, People's Hospital of Zhengzhou University, Zhengzhou 450003, China.
出版信息
Zhonghua Yi Xue Za Zhi. 2021 Apr 27;101(16):1178-1181. doi: 10.3760/cma.j.cn112137-20201207-03281.
The data of 9 patients with stage Ⅲ/Ⅳ extranodal nasal-type natural killer/T cell lymphoma from August 2019 to August 2020 in People's Hospital of Zhengzhou University was retrospectively analyzed. All the patients were treated with the programmed cell death-1 (PD-1) inhibitor combined with P-GemoX-DEX (gemcitabine+oxaliplatin+dexamethasone+peraspartase) regimen as the first-line treatment. After 4 cycles of treatment, positron emission tomography/computed tomography (PET/CT) was used to evaluate the curative effect, and adverse reactions were also observed. The median follow-up time was 7 months. The overall response rate, complete and partial remission rate was 9/9, 6/9 and 3/9, respectively. The main adverse event was hematological toxicity, with 6 cases of grade Ⅰ/Ⅱ neutropenia, and no immune-related adverse events were reported.
回顾性分析了2019年8月至2020年8月在郑州大学人民医院就诊的9例Ⅲ/Ⅳ期结外鼻型自然杀伤/T细胞淋巴瘤患者的数据。所有患者均采用程序性细胞死亡蛋白1（PD-1）抑制剂联合P-GemoX-DEX（吉西他滨+奥沙利铂+地塞米松+培门冬酶）方案作为一线治疗。治疗4个周期后，采用正电子发射断层扫描/计算机断层扫描（PET/CT）评估疗效，并观察不良反应。中位随访时间为7个月。总缓解率、完全缓解率和部分缓解率分别为9/9、6/9和3/9。主要不良事件为血液学毒性，Ⅰ/Ⅱ级中性粒细胞减少6例，未报告免疫相关不良事件。
Zotero 插件